A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Dae-Won | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Kim, Hee-Jun | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Tae-You | - |
dc.date.available | 2019-01-22T14:04:01Z | - |
dc.date.issued | 2018-03-05 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1084 | - |
dc.description.abstract | Background: Oxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicenter, openlabel, single-arm phase II trial that evaluated the efficacy of S-1 and oxaliplatin (SOX) in advanced hepatocellular carcinoma. All patients included in the present study were systemic treatment-naive. Prior treatment with sorafenib was allowed, but other treatments were not. Methods: Patients received S-1 (40 mg/m(2) twice daily from day 1-14) and oxaliplatin (130 mg/m(2) on day 1) every 3 weeks. The primary end point was time to progression (TTP). Secondary end points included progression-free survival, overall survival (OS), response rate, and safety profile. Results: Thirty six patients with advanced hepatocellular carcinoma were included in this study. The median TTP was 3. 0 months (95% confidence interval (CI), 0.75-5.25), and the median OS was 10.3 months (95% CI, 6.4-14.3). Bone metastasis was associated with poorer TTP and OS. The efficacy of SOX was unaffected by prior sorafenib or locoregional therapy. The objective response rate was 13.9%. No grade 4 toxicity or death from adverse events occurred. The most common grade 3 toxicities were neutropenia (13.9%), thrombocytopenia (13.9%), and diarrhea (8.3%). Conclusions: Although this trial did not meet its primary end point, the SOX regimen showed comparable efficacy and safety to the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen. As the SOX regimen is easier for patients, SOX may be a reasonable substitute for FOLFOX in hepatocellular carcinoma. | - |
dc.publisher | BIOMED CENTRAL LTD | - |
dc.title | A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12885-018-4039-9 | - |
dc.identifier.bibliographicCitation | BMC CANCER, v.18, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000427087100004 | - |
dc.identifier.scopusid | 2-s2.0-85043347398 | - |
dc.citation.number | 1 | - |
dc.citation.title | BMC CANCER | - |
dc.citation.volume | 18 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Phase II | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | S-1 | - |
dc.subject.keywordPlus | METASTATIC COLORECTAL-CANCER | - |
dc.subject.keywordPlus | PLUS OXALIPLATIN | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | BRIVANIB | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.